Clementia Pharmaceuticals Inc (NASDAQ:CMTA) – Leerink Swann issued their FY2022 earnings per share estimates for shares of Clementia Pharmaceuticals in a research report issued to clients and investors on Tuesday. Leerink Swann analyst J. Schwartz forecasts that the company will post earnings per share of $1.35 for the year.
A number of other research firms have also weighed in on CMTA. Zacks Investment Research raised shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 30th. Wedbush reissued an “outperform” rating and issued a $26.00 target price on shares of Clementia Pharmaceuticals in a report on Tuesday, November 14th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $27.00.
Clementia Pharmaceuticals (NASDAQ:CMTA) traded down $0.70 during mid-day trading on Thursday, hitting $13.23. 105,439 shares of the company were exchanged, compared to its average volume of 86,298. Clementia Pharmaceuticals has a 1 year low of $11.72 and a 1 year high of $20.15.
A number of hedge funds and other institutional investors have recently bought and sold shares of CMTA. Orbimed Advisors LLC purchased a new position in Clementia Pharmaceuticals during the third quarter worth $176,082,000. Janus Henderson Group PLC purchased a new position in Clementia Pharmaceuticals during the third quarter worth $12,833,000. JPMorgan Chase & Co. purchased a new position in Clementia Pharmaceuticals during the third quarter worth $10,937,000. Perceptive Advisors LLC purchased a new position in Clementia Pharmaceuticals during the third quarter worth $6,291,000. Finally, Sphera Funds Management LTD. purchased a new position in Clementia Pharmaceuticals during the third quarter worth $2,753,000. 73.82% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/23/clementia-pharmaceuticals-inc-forecasted-to-post-fy2022-earnings-of-1-35-per-share-cmta.html.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.